药品监管科学研究之基因和细胞治疗产品Ⅱ:我国监管体系的完善建议

Scientific Research Ⅱ on the Inspection of Gene and Cell Therapy Products: Suggestions on Improving the Regulatory System in China

目的:为完善我国基因和细胞治疗产品监管体系提供参考。方法:对美国、欧盟和日本等监管机构的基因和细胞治疗产品监管体系进行对比研究,结合对我国相关行业开展的问卷调研结果进行综合分析。结果与结论:从药品生命周期管理的角度,提出完善我国基因和细胞治疗产品监管体系的建议,包括我国基因和细胞治疗产品监管体系完善的原则与思路、基因和细胞治疗产品不同生命周期的个性化监管要求、细胞治疗产品双轨制的构建与完善建议,以及提高基因和细胞治疗产品可及性的措施。

Objective: To provide references for improving the regulatory system of China’s gene and cell therapy products. Methods: A comparative study on the regulatory systems of gene and cell therapy products in the United States, the European Union and Japan was carried out, combined with the results of questionnaire surveys conducted in China by the relevant industries. Results and Conclusion: From the perspective of drug life cycle management, suggestions for improving the regulatory system of China’s gene and cell therapy products were proposed, which included suggestions about the principles and ideas for improving the regulatory system of gene and cell therapy products in China, the personalized regulatory requirements for gene and cell therapy products in different life cycles, the construction and improvement of the dual-track system of cell therapy products, as well as the measures to improve the availability of gene and cell therapy products.